Aggregator

Različiti antibiotici za liječenje upale grla uzrokovane streptokokom skupine A

1 year 6 months ago
Različiti antibiotici za liječenje upale grla uzrokovane streptokokom skupine A Koji je antibiotik bolji za faringitis (upalu grla)? Ključne poruke Učinak na povlačenje simptoma grlobolje/faringitisa uzrokovanog beta-hemolitičkim streptokokom skupine A (BHS-A) bio je sličan kod različitih antibiotika. Svi antibiotici mogu uzrokovati nuspojave. Što je faringitis? Faringitis (ili upala grla) je upala koju uzrokuju virusi ili bakterije (npr. beta-hemolitički streptokok skupine A). Obično prođe bez liječenja. Rizik od komplikacija iznimno je nizak za većinu ljudi u zemljama s visokim dohotkom....

Koje su dobrobiti i rizici programa zdravstvenog opismenjavanja za migrante?

1 year 6 months ago
Koje su dobrobiti i rizici programa zdravstvenog opismenjavanja za migrante? Zdravstvena pismenost označava znanje, motivaciju i kompetencije (npr. sposobnosti čitanja i pisanja) koje su ljudima potrebne za pronalaženje, razumijevanje, procjenu i korištenje zdravstvenih informacija. Migranti su izloženi riziku od poteškoća sa zdravstvenom pismenosti (npr. kada ne poznaju dobro zdravstveni sustav države). „Generička” zdravstvena pismenost omogućava ljudima pronalaženje, razumijevanje i korištenje općih zdravstvenih informacija kako bi donosili zdravstvene odluke. Zdravstvena pismenost „o...

Brusnice za sprječavanje infekcija mokraćnog sustava

1 year 6 months ago
Brusnice za sprječavanje infekcija mokraćnog sustava Što je proučavano u ovom sustavnom pregledu? Brusnice (sok od brusnice, tablete ili kapsule) se već godinama koriste za prevenciju infekcija mokraćnog sustava (IMS). Brusnice sadrže proantocijanidine (PAC), tvari koje mogu spriječiti prianjanje bakterija na stijenke mjehura. To može pomoći u sprječavanju infekcija i smanjiti vrijeme provedeno kod liječnika. Međutim, trenutno ne postoji utvrđeni režim doziranja PAC niti formalna regulacija proizvoda od brusnice. Konkretno, postoji mogućnost da preporučene doze ne budu navedene na pakiranju....

Liječenje buloznog pemfigoida

1 year 6 months ago
Liječenje buloznog pemfigoida Koji su pristupi najučinkovitiji u liječenju buloznog pemfigoida (rijetka bolest kože koja uzrokuje mjehuriće, svrbež i suhu kožu)? Ključne poruke • Krema koja sadrži lokalni steroid klobetazol propionat, primijenjena na cijeloj površini kože, jednako je učinkovita kao oralna terapija steroidima (prednizon), uzrokuje manje ozbiljnih neželjenih ili štetnih učinaka i može smanjiti smrtnost. • Početno liječenje doksiciklinom (200 mg dnevno), antibiotikom protuupalnog djelovanja, dovodi do prihvatljive kontrole mjehura kože u kratkoročnom razdoblju u usporedbi s...

Nebulizatori za primjenu lijekova za cističnu fibrozu

1 year 6 months ago
Nebulizatori za primjenu lijekova za cističnu fibrozu Ključne poruke 1. Novije tehnologije imaju prednosti u odnosu na konvencionalne sustave u smislu trajanja liječenja, količine lijeka koja dolazi do pluća, preferencija pacijenata i pridržavanja uzimanju terapije. 2. Ne mogu se svi lijekovi koji se koriste u liječenju cistične fibroze primijeniti istim nebulizatorom, a nedostaju podatci za neke od različitih kombinacija nebulizatora i lijekova. 3. Potrebna su dugoročna istraživanja za procjenu različitih sustava nebulizatora kako bi se odredili ishodi usmjereni na pacijenta (kao što je...

Koristi i rizici operativnog i neoperativnog liječenja slomljene petne kosti

1 year 6 months ago
Koristi i rizici operativnog i neoperativnog liječenja slomljene petne kosti Ključne poruke • Kod osoba koje su slomile petnu kost, operacija može poboljšati funkcionalnost stopala i gležnja do dvije godine nakon ozljede u usporedbi s neoperativnim liječenjem. • Operacija također može smanjiti broj ljudi koji pate od bolova do dvije godine nakon ozljede te može neznatno poboljšati njihovu kvalitetu života. • Dokazi su proizašli samo iz nekoliko manjih istraživanja koja nisu uvijek bila dobro provedena, što znači da dokazi nisu u potpunosti pouzdani. • Potrebno je više dobro provedenih...

Cochrane International Mobility - Milena Geist

1 year 6 months ago

Cochrane's members and supporters come from more than 130 countries, worldwide. Our volunteers and contributors are researchers, health professionals, patients, carers, people passionate about improving health outcomes for everyone, everywhere.

Getting involved in Cochrane’s work means becoming part of a global community. The Cochrane International Mobility programme connects successful applicants with a placement in a host Cochrane Group, where they learn about the production, use, and knowledge translation of Cochrane reviews. The prgramme offers opportunities for learning and training not only for participants but also for host staff.

In this series, we profile those who have participated in the Cochrane International Mobility Program and learn more about their experiences.

Name: Milena
Location: Germany
CIM Location: Cochrane Sweden

How did you first learn about Cochrane? 
I first learned about Cochrane in my Bachelor studies back in Munich. In some of our research modules several lecturers mentioned systematic reviews by Cochrane having the highest level of evidence and being internationally renowned in research. In my Master studies it was mandatory to complete an internship and I wanted to take the opportunity to go abroad. Back in Germany, I worked in a research team at the 'Haunersche children's hospital'. My boss, who has completed a Cochrane course before, contacted Martin who forwarded contact to Matteo and introduced me to Cochrane Sweden and its department for Neonatology. 

What was your experience with your Cochrane International Mobility? 
Since my Bachelor studies, I've always been interested in the field of research and worked in several jobs regarding the health of children and adolescents. Conducting a systematic review in the field of Neonatology was one thing I was still missing. Cochrane has proved to be an outstanding place of internship: the content is high-quality, the communication runs smoothly and the supervision is excellent. I really liked working in such an international team.

What are you doing now in relation to your Cochrane International Mobility experience? 
Right now, we have just finished a Cochrane review about strategies for cessation of caffeine administration in preterm infants. Additionally, I am collaborating with other amazing teams in a review protocol regarding infant positioning as well as a methods paper about imputing risk ratio from rate data. Also, I am planning to remain a part of Cochrane. Back home, I will continue to support Matteo's team and several Cochrane projects. Cochrane's mobile way of working is just super flexible and works perfect for students from all over the world.

Do you have any words of advice to anyone considering a Cochrane International Mobility experience? 
If you're interested in research and how to perform a high-standard systematic review in practice, Cochrane is the perfect place for you. The intense exchange with international researchers, doctors, nurses, statisticians and students allows you to grow, personally as well as professionally. It will improve your English skills, your communication skills, and your knowledge about methodology in research a lot. I can deeply recommend working together with Cochrane!

Monday, November 6, 2023
Muriah Umoquit

Cochrane seeks Executive Assistant to Editor in Chief

1 year 6 months ago

Specifications: Permanent – Full Time
Salary:  £32,000 per Annum
Location: (Remote – Flexible) Candidates anywhere from the world will be considered; however, Cochrane’s Central Executive Team is only able to offer consultancy contracts outside these countries.
Closing date:  12 November 2023

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into four directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

The Executive Assistant role will provide an efficient and responsive administrative, organisational, and logistical service to the Editor in Chief (EiC) and the leadership team of the Evidence Production & Methods Directorate (EPM). As well as support the operational activities of the directorate, including management of the Editorial Board.
      
Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

  • An opportunity to truly impact health globally
  • A flexible work environment
  • A comprehensive onboarding experiences
  • An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

  • For further information on the role and how to apply, please click here.
  • The deadline to receive your application is 12 November 2023.
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Read our Recruitment Privacy Statement
Monday, November 6, 2023 Category: Jobs
Lydia Parsonson

Temperatura i uvjeti skladištenja humanog inzulina

1 year 6 months ago
Temperatura i uvjeti skladištenja humanog inzulina Što je inzulin? Inzulin je hormon koji proizvodi gušterača, a pomaže vašem tijelu pretvoriti hranu u energiju te kontrolira razinu šećera u krvi. Dijabetičari ne mogu proizvesti dovoljno inzulina ili ga učinkovito iskoristiti, pa ga neki moraju sami ubrizgavati. Kako treba skladištiti inzulin? Zdravstvena tijela i proizvođači lijekova preporučuju držati inzulin podalje od sunčeve svjetlosti, ne zamrzavati ga i čuvati ga u hladnjaku. Neotvorene bočice ili spremnici humanog inzulina te ulošci za inzulinske olovke trebaju se čuvati na...

Koje su dobrobiti i štete lijekova za povećanje protoka krvi (inhibitora fosfodiesteraze tipa 5 (PDE5i)) u usporedbi s placebom za liječenje Raynaudovog fenomena?

1 year 6 months ago
Koje su dobrobiti i štete lijekova za povećanje protoka krvi (inhibitora fosfodiesteraze tipa 5 (PDE5i)) u usporedbi s placebom za liječenje Raynaudovog fenomena? Ključne poruke PDE5 inhibitori mogu neznatno smanjiti učestalost i trajanje napadaja Raynaudovog fenomena i mogu poboljšati pacijentovu opću procjenu bolesti, ali vjerojatno malo ili nimalo ne utječu na bol u usporedbi s placebom. Nije jasno imaju li PDE5 inhibitori učinka na jačinu napadaja bolesti. U usporedbi s ljudima liječenim placebom, za osobe liječene inhibitorima PDE5 vjerojatnije je da će ranije završiti s liječenjem, ali...

Početna hrana za dojenčad s većim udjelom bjelančevina u usporedbi s početnom hranom za dojenčad s manjim udjelom bjelančevina: koja bolje sprječava pojavu pothranjenosti i pretilosti u dojenčadi?

1 year 6 months ago
Početna hrana za dojenčad s većim udjelom bjelančevina u usporedbi s početnom hranom za dojenčad s manjim udjelom bjelančevina: koja bolje sprječava pojavu pothranjenosti i pretilosti u dojenčadi? Ključne poruke 1. Nije jasno utječe li početna hrana za dojenčad s većim udjelom bjelančevina na pothranjenost ili pretilost u dojenčadi. 2. Potrebna su opsežnija istraživanja kako bi se dodatno procijenile dobrobiti i potencijalne štete različitih vrsta početne hrane za dojenčad. 3. Buduća bi se istraživanja trebala usredotočiti na dugoročni rast i razvoj mozga. Što je početna hrana za dojenčad s...

Primjena antioksidansa u odraslih s kroničnom bolesti bubrega

1 year 7 months ago
Primjena antioksidansa u odraslih s kroničnom bolesti bubrega Osobe s kroničnom bolesti bubrega imaju visok rizik od rane smrti, kardiovaskularnih bolesti (bolest srca i moždani udar) ili zatajenja bubrega (dijaliza ili transplantacija bubrega). Antioksidansi, poput vitaminskih dodataka, mogu biti lako dostupna intervencija za smanjenje tih visokih rizika. Kako je proveden ovaj sustavni pregled? Autori Cochraneovog sustavnog pregleda pretraživali su literaturu objavljenu do studenog 2022. godine te su procijenili učinke antioksidansa na smrtnost, kardiovaskularne bolesti, bolesti bubrega i...

HINTS test za uzroke akutne vrtoglavice

1 year 7 months ago
HINTS test za uzroke akutne vrtoglavice Ključne poruke Pregledi HINTS i HINTS Plus bili su prilično točni u dijagnosticiranju centralnog uzroka akutnog vestibularnog sindroma (AVS). Što je akutni vestibularni sindrom? Akutni vestibularni sindrom je specifični tip vrtoglavice, koji uključuje jaku vrtoglavicu (osjećaj vrtnje), mučninu i povraćanje, nistagmus (nehotične pokrete očiju), ili nestabilnost. Akutni vestibularni sindrom može biti posljedica perifernih uzroka (onih unutar ušnog kanala) ili centralnih uzorka (onih unutar mozga). Liječnici mogu procijeniti uzrok pomoću rizičnih...

Human insulin less temperature-sensitive than previously thought

1 year 7 months ago

A new Cochrane review has found that insulin can be kept at room temperature for months without losing potency, offering hope to people living with diabetes in regions with limited access to healthcare or stable powered refrigeration. This affects millions of people living in low- and middle-income countries, particularly in rural areas, as well as people whose lives have been disrupted by conflict or natural disasters.

Human insulin is a hormone produced by the body that helps turn food into energy and controls blood sugar levels. People with diabetes cannot make enough insulin and those with type 1 diabetes have to inject insulin several times a day, typically before every meal. Insulin is an essential medicine for people with diabetes and current guidance states that before use it must be kept refrigerated to preserve its effectiveness.

For millions of people with diabetes living in low- and middle-income countries, however, the harsh reality is that electricity and refrigeration are luxuries that are unavailable to them. Vulnerable populations in war-torn areas, disaster-prone regions, and climate crisis-affected areas, including those enduring extreme heat, also need solutions that don’t rely on powered fridges.

The new Cochrane review summarizes results of different studies investigating what happens to insulin when stored outside of fridges, including previously unpublished data from manufacturers. The review found that it is possible to store unopened vials and cartridges of specific types of human insulin at temperatures of up to 25°C for a maximum of six months, and up to 37°C for a maximum of two months, without any clinically relevant loss of insulin activity. Data from one study showed no loss of insulin activity for specific insulin types when stored in oscillating ambient temperatures of between 25°C and 37°C for up to three months. This fluctuation resembles the day-night temperature cycles experienced in tropical countries.

The research team, led by Bernd Richter from the Institute of General Practice, Medical Faculty of the Heinrich-Heine-University in Düsseldorf, Germany, conducted comprehensive research to investigate insulin stability under various storage conditions. The review analyzed a total of seventeen studies, including laboratory investigations of insulin vials, cartridges/pens, and prefilled syringes, demonstrating consistent insulin potency at temperatures ranging from 4 °C to 37 °C, with no clinically relevant loss of insulin activity.

Bernd stressed the significance of this research, particularly for people living with type 1 diabetes, where "insulin is a lifeline, as their very lives depend on it. While type 2 diabetes presents its challenges, type 1 diabetes necessitates insulin for survival. This underscores the critical need for clear guidance for people with diabetes in critical life situations, which many individuals lack from official sources.

"Our study opens up new possibilities for individuals living in challenging environments, where access to refrigeration is limited. By understanding the thermal stability of insulin and exploring innovative storage solutions, we can make a significant impact on the lives of those who depend on insulin for their well-being."

These findings can help communities facing challenges in securing constant cold storage of insulin. They provide reassurance that alternatives to powered refrigeration of insulin are possible without compromising the stability of this essential medicine. It suggests that if reliable refrigeration is not possible, room temperature can be lowered using simple cooling devices such as clay pots for insulin storage.

The researchers have also identified uncertainties for future research to address. There remains a need to better understand insulin effectiveness following storage under varying conditions. Further research is also needed on mixed insulin, influence of motion for example when insulin pumps are used, contamination in opened vials and cartridges, and studies on cold environmental conditions.

Friday, November 3, 2023
Muriah Umoquit

Cochrane seeks Fundraising Manager

1 year 7 months ago

Specifications: Permanent – Full Time
Salary:  £45,000 per Annum  
Location: (Remote – Flexible) Ideally based in the UK, Germany or Denmark. Candidates anywhere from the world will be considered; however, Cochrane’s Central Executive Team is only able to offer consultancy contracts outside these countries for 1-Year.
Closing date: 29 January 2024

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into four directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

We are seeking a self-starter; an experienced and energetic team member with a proven track-record of successfully securing five and six figure gifts from a wide range of donors. You have experience of fundraising from high-value Global trusts and foundations, as well as from government or multilateral donors (e.g. the United Kingdom’s Foreign, Commonwealth & Development Office and the European Union).  

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.  

You can expect: 

  • An opportunity to truly impact health globally  
  • A flexible work environment  
  • A comprehensive onboarding experiences
  • An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

  • For further information on the role and how to apply, please click here
  • The deadline to receive your application is 29 January 2024.
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
  • Read our Recruitment Privacy Statement
Thursday, January 18, 2024 Category: Jobs
Lydia Parsonson